Free Submission Public Relations &
Deutsch English


Atacand (Chronic Heart Failure) - Forecast and Market Analysis to 2022 - New Market Report

Print article Print article
2013-08-13 01:13:34 - Fast Market Research recommends "Atacand (Chronic Heart Failure) - Forecast and Market Analysis to 2022" from GlobalData, now available

The chronic heart failure (CHF) market is a mature market that has been slowly overtaken by generic drugs, and more branded products are expected to lose market exclusivity during the next few years. GlobalData predicts that the major global barriers that will play a crucial role in narrowing the global growth of the CHF market over the forecast period include the sparsely populated CHF pipeline and an increasing number of generic competitors in a market that is already heavily laden with generic drugs. However, the market entry of entry of Novartis' LCZ-696, the first novel, branded CHF drug to enter the market in five years, will noticeably enhance the overall market size during the forecast period. LCZ-696 is currently being

evaluated in a trial for patients with heart failure with reduced ejection fraction (HF-REF), but if clinical trial data continue to demonstrate the drug's efficacy in patients with heart failure with preserved ejection fraction (HF-PEF), and it gains approval for use in this population, it will be the first drug to show efficacy in this largely underserved patient population. In addition, increased use of MRAs over the forecast period in all seven major markets (7MM) will contribute to the increase in the global CHF market size.

Full Report Details at
- ..

AstraZeneca's Atacand (candesartan) blocks the binding of angiotensin II to its receptor, inhibiting the effects of angiotensin, which include vasoconstriction, synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. It was launched for the treatment of hypertension in 1998 in the US, Europe, and Japan. In Japan, it is marketed by Takeda under the brand name Blopress. In 2004, 2005, and 2008, Atacand was approved for the treatment of CHF in Europe, the US, and Japan, respectively.


* Overview of chronic heart failure, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Atacand including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Atacand for the top seven countries from 2012 to 2022.
* Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for chronic heart failure
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Atacand performance
* Obtain sales forecast for Atacand from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

Report Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Prognosis
3.3 Quality of Life
3.4 Symptoms
4 Disease Management
4.1 Treatment Overview
4.1.1 Pharmacological Treatments
4.1.2 Mechanical Devices
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Atacand (candesartan)
6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast
7 Appendix
7.1 Bibliography
7.2 Abbreviations
7.3 Methodology
7.4 Forecasting Methodology
7.4.1 NYHA Class Segmentation of Total Prevalent CHF Population
7.4.2 Diagnosed CHF Population
7.4.3 Drug-Treated CHF Population
7.4.4 Patient Population Breakdown: HF-REF versus HF-PEF
7.4.5 Treatment of HF-REF versus HF-PEF
7.4.6 General Pricing Assumptions
7.4.7 Drugs Assumptions
7.4.8 Generic Erosion
7.5 Physicians and Specialists Included in this Study
7.6 Survey of Prescribing Physicians
7.7 About the Authors
7.7.1 Author
7.7.2 Global Head of Healthcare
7.8 About GlobalData
7.9 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Leading Causes of CHF
Table 2: Other Causes of CHF
Table 3: Compensatory Mechanisms in CHF
Table 4: Typical Symptoms of CHF
Table 5: NYHA Classification of HF Based on Symptoms and Physical Ability of Patients
Table 6: ACC/AHA Classification of HF Based on Disease Progression
Table 7: NYHA Classification of HF Based on Symptoms and Physical Activity of Patients
Table 8: Commonly Used Treatment Guidelines for CHF
Table 9: Most Prescribed Drugs for CHF by NYHA Class in the Major Markets, 2012
Table 10: Select Products Used for CHF Treatment, 2012
Table 11: Product Profile - Atacand
Table 12: Atacand SWOT Analysis, 2012
Table 13: Global Sales Forecasts ($m) for Atacand, 2012-2022
Table 14: Physicians Surveyed, By Country

List of Figures

1.2 List of Figures
Figure 1: Worsening HF Leading to Chronic Disease
Figure 2: Drug-Treatment Rates of Patients Diagnosed with CHF in the 7MM, by NYHA Class

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Bill Thompson
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact